Pre-Exposure Prophylaxis

Twice-yearly injectable lenacapavir for HIV prevention reduced HIV infections by 96% compared with background HIV incidence and demonstrated superiority over a once-daily pill for PrEP in a phase 3 trial, Gilead Sciences announced Thursday.

Testing HIV PrEP users for STIs every 6 months did not increase the risk for STIs compared with testing them every 3 months and could reduce the cost of PrEP programs, according to a study.

A 60-year-old man in Germany became the seventh person to be considered potentially cured of HIV after receiving a stem cell transplant from a person with a genetic mutation that prevents infection.

Long-acting injectable PrEP is feasible and acceptable to both men and women, according to a study presented at the AIDS 2024 meeting in Munich.

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.

Use of an electronic health record-based intervention significantly increased PrEP use among patients of primary care physicians who care for people with HIV, a randomized trial found.

DENVER — Giving patients the option of choosing long-acting PrEP resulted in a fivefold increase in coverage and a reduction in HIV incidence during the SEARCH trial in Uganda, researchers reported.

DENVER — New data from a cohort of adolescent and young women in sub-Saharan Africa showed a higher level of HIV PrEP adherence than has been reported in previous studies, researchers said.

DENVER — A new study provides reassurances that PrEP can reliably prevent HIV in cisgender women, even if they do not use it daily.